X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 39.4 20.2 194.4% View Chart
P/BV x 11.4 3.6 314.3% View Chart
Dividend Yield % 0.5 0.3 161.4%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
GLENMARK PHARMA
Mar-17
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs5,190993 522.7%   
Low Rs4,351729 596.6%   
Sales per share (Unadj.) Rs1,382.9325.5 424.8%  
Earnings per share (Unadj.) Rs130.239.3 331.3%  
Cash flow per share (Unadj.) Rs137.948.7 283.4%  
Dividends per share (Unadj.) Rs40.002.00 2,000.0%  
Dividend yield (eoy) %0.80.2 361.0%  
Book value per share (Unadj.) Rs652.7159.2 409.9%  
Shares outstanding (eoy) m21.25282.17 7.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.6 130.4%   
Avg P/E ratio x36.621.9 167.2%  
P/CF ratio (eoy) x34.617.7 195.5%  
Price / Book Value ratio x7.35.4 135.1%  
Dividend payout %30.75.1 603.6%   
Avg Mkt Cap Rs m101,373242,991 41.7%   
No. of employees `0003.113.0 23.8%   
Total wages/salary Rs m3,45316,408 21.0%   
Avg. sales/employee Rs Th9,531.97,083.9 134.6%   
Avg. wages/employee Rs Th1,119.91,265.4 88.5%   
Avg. net profit/employee Rs Th897.3855.1 104.9%   
INCOME DATA
Net Sales Rs m29,38791,857 32.0%  
Other income Rs m576374 154.3%   
Total revenues Rs m29,96392,230 32.5%   
Gross profit Rs m3,97320,367 19.5%  
Depreciation Rs m1642,644 6.2%   
Interest Rs m202,373 0.9%   
Profit before tax Rs m4,36515,724 27.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,5983,827 41.8%   
Profit after tax Rs m2,76711,088 25.0%  
Gross profit margin %13.522.2 61.0%  
Effective tax rate %36.624.3 150.5%   
Net profit margin %9.412.1 78.0%  
BALANCE SHEET DATA
Current assets Rs m18,90668,746 27.5%   
Current liabilities Rs m6,29727,027 23.3%   
Net working cap to sales %42.945.4 94.5%  
Current ratio x3.02.5 118.0%  
Inventory Days Days6285 73.2%  
Debtors Days Days2296 22.6%  
Net fixed assets Rs m1,15924,132 4.8%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m13,65744,643 30.6%   
Net worth Rs m13,86944,925 30.9%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m20,638117,639 17.5%  
Interest coverage x215.07.6 2,819.0%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.40.8 182.4%   
Return on assets %13.511.4 118.0%  
Return on equity %19.924.7 80.8%  
Return on capital %31.619.1 165.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m056,152 0.0%   
Fx outflow Rs m08,084 0.0%   
Net fx Rs m048,068 0.0%   
CASH FLOW
From Operations Rs m3,0726,574 46.7%  
From Investments Rs m-1,554-7,124 21.8%  
From Financial Activity Rs m-8985,432 -16.5%  
Net Cashflow Rs m6211,992 31.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 22, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS